• Oct 6, 2026

  $402.60-0.09%

  Amgen closed down 0.09%, barely changed, while comparable biological products companies fell 2.01% on average, with 5 of 6 falling [1]. The move was therefore not shared: Amgen was nearly flat against a weaker cohort. Volume was 0.6x its trailing 20-session average [2].

  • 1Peer group
  • 2Market data

• Oct 5, 2026

  $402.98-0.01%

  Amgen closed down 0.01%, essentially flat, while comparable biological products companies rose 1.76% on average, with 5 of 6 rising [1]. The cohort's gain was not matched by Amgen.

  • 1Peer group

• Oct 2, 2026

  $403.04-1.04%

• Oct 1, 2026

  $407.27-3.38%

  Comparable listed companies in Biological Products fell 0.93% on average, with 5 of 6 declining [1]. Amgen's 3.38% drop was larger than the cohort's average move [1].

  • 1Peer group

• Sep 30, 2026

  $421.51-0.50%

  Amgen fell 0.50%, a smaller decline than the comparable biological products companies, which moved -0.81% on average [3]. Four of the six peers fell and two rose [3]. Seeking Alpha also carried stories about an FDA recruitment drive for advisory panels and a new CEO at the pharmaceutical lobbying group PhRMA, but neither was tied to Amgen's move [1][2].

  • 1Seeking Alpha
  • 2Seeking Alpha
  • 3Peer group

• Sep 29, 2026

  $423.64+1.32%

• Sep 28, 2026

  $418.13+0.85%

  Seeking Alpha reported that the FDA approved Teva's Degevma, a biosimilar of Amgen's Xgeva for cancer-related bone complications [1]. The shares closed up 0.85% that day, and the item does not say whether the approval affected the price.

  • 1Seeking Alpha

Closing prices for AMGN. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.